Evidence of the value of pharmacogenomic testing is needed to inform policymakers and clinicians for decision making related to adoption and coverage, and to facilitate prioritization for research and development. Pharmacogenomics has an important role in creating a more efficient healthcare system, and this article addresses how economic evaluation can strategically target evidence gaps for public health priorities with examples from pharmacogenomic medicine. This article begins with a review of the need for and use of economic evaluations in value-based decision making for pharmacogenomic testing. Three important gaps are described with examples demonstrating how they can be addressed: (1) projected impact of hypothetical new technology, (2) pre-implementation assessment of a specific technology, and (3) post-implementation assessment from relevant analytical stakeholder perspectives. Additional needs, challenges and approaches specific to pharmacogenomic economic evaluation in the developing world are also identified. These pragmatic approaches can provide much needed evidence to support real-world value-based decision making for pharmacogenomic-based screening and treatment strategies.

Comparative effectiveness, Cost-benefit analysis, Cost-utility analysis, Decision making, Diagnostics, Economics, Personalized genomics, Value
dx.doi.org/10.1159/000366177, hdl.handle.net/1765/92065
Public Health Genomics
Department of Clinical Chemistry

Snyder, S.R, Mitropoulou, C, Patrinos, G.P, & Williams, M.S. (2014). Economic evaluation of pharmacogenomics: A value-based approach to pragmatic decision making in the face of complexity. Public Health Genomics, 17, 256–264. doi:10.1159/000366177